Hospital Profile
Name | Central Vermont Medical Center |
---|
Type | Acute Care Hospital |
---|
Location | Box 547, Barre, Vermont |
---|
Ownership | Voluntary non-profit - Private |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 470001 |
Patients' Experience Survey:
Overall Rating of the Hospital:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Central Vermont Medical Center from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1508845637 |
Organization Name | CENTRAL VERMONT MEDICAL CENTER INC |
Doing Business As | CENTRAL VERMONT MEDICAL CENTER INC. |
Address | 130 Fisher Rd, Berlin, VT 05602 |
Hospital Type | General Acute Care Hospital |
Phone Number | 802-371-4100 |
News Archive
Research shows how viruses inactivate immune system, causing cancer
It's no new news that viruses cause cancer. For example, human papillomavirus causes almost all of the more than 500,000 annual worldwide cases of cervical cancer.
Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile
Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.
Targacept commences AZD3480 Phase 2b study in Alzheimer's disease
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer's disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration.
Women are 25% less likely to die post TAVI than men, says doctor
Dr Sherif said: "Earlier studies on the impact of gender on outcome after transcatheter aortic valve implantation (TAVI) have had conflicting results. A Canadian study reported in 641 consecutive patients that female sex is associated with a better long-term and short-term survival after TAVI.1 An Italian study of 305 high risk patients found no gender differences in composite safety and efficacy endpoints at 30 days and one year after TAVI."2
Read more Medical News
› Verified 4 days ago
Structural Quality Measures:
Able to receive lab results electronically | No |
Able to track patients' lab results, tests, and referrals electronically between visits | No |
News Archive
Research shows how viruses inactivate immune system, causing cancer
It's no new news that viruses cause cancer. For example, human papillomavirus causes almost all of the more than 500,000 annual worldwide cases of cervical cancer.
Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile
Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.
Targacept commences AZD3480 Phase 2b study in Alzheimer's disease
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer's disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration.
Women are 25% less likely to die post TAVI than men, says doctor
Dr Sherif said: "Earlier studies on the impact of gender on outcome after transcatheter aortic valve implantation (TAVI) have had conflicting results. A Canadian study reported in 641 consecutive patients that female sex is associated with a better long-term and short-term survival after TAVI.1 An Italian study of 305 high risk patients found no gender differences in composite safety and efficacy endpoints at 30 days and one year after TAVI."2
Read more News
› Verified 4 days ago